Benefits (Research Focus) NNMT inhibition studied as a selective small-molecule inhibitor of nicotinamide N-methyltransferase NAD+ preservation investigated for preservation of cellular NAD+ pools and downstream sirtuin pathway activity Adipose tissue research explored for lipolysis markers and fat-mass partitioning in DIO rodent models Skeletal muscle metabolism examined for endpoints related to muscle aging and sarcopenia models Metabolic signaling researched for glucose homeostasis and insulin sensitivity endpoints in metabolic disease models What Researchers Look At NNMT enzymatic activity and 1-methylnicotinamide (1-MNA) tissue concentrations Intracellular NAD+ / NADH ratio and downstream sirtuin (SIRT1/SIRT3) activation Body composition, fat mass, and lean mass partitioning in DIO rodent models Adipocyte lipolysis markers and adipose tissue inflammation profiles Glucose tolerance, insulin sensitivity, and hepatic steatosis endpoints Quick Specs Form: Lyophilized white powder Net Content: 50 mg per vial (as iodide salt) Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: 5-Amino-1MQ (5-Amino-1-methylquinolinium iodide) Synonyms: 5-Amino-1-methylquinolinium

Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
Trademark Information: BioGlute is a registered trademark of Essential Nutraceuticals LLC, Setria is a registered trademark of KYOWA HAKKO BIO Co., Ltd
If your energy is flat and your output isn't matching your effort, those are the first two places to look before you change your program
S.ParamakrishnanN.SureshB
151 PaolicchiA.SotiropuolouM.PeregoP.DaubeufS.VisvikisA.LorenziniE.et al (2003)